Table 1.

Comparison of Palivizumab Label and the History of RSV Immunoprophylaxis Policies.

Condition	Palivizumab-approved label (MedImmune, LLC, 2014)	AAP 2014 and AAP 2019 guidance (AAP Committee on Infectious Diseases & AAP Bronchiolitis Guidelines Committee, 2014a; AAP Committee on Infectious Diseases & AAP Bronchiolitis Guidelines Committee, 2014b)	NPA 2018 guidelines (Goldstein et al., 2017)
Preterm	All infants born at or before 35 wGA and aged 6 months or younger at the start of RSV season	All infants born at less than 29wGA and aged younger than 12 months at the start of RSV season	All infants born at or before 28wGA and aged younger than 12 months at the start of RSV season All infants 29–32 wGA aged younger than 6 months at the start of RSV season All infants 33–35 wGA aged younger than 6 months at the start of RSV season with additional risk factors
BPD/CLDP	Children 24 months of age or younger at the start of RSV season who required additional medical support in past 6 months	All infants born at less than 32wGA and requiring oxygen for at least the first 28 days post-birth All those aged younger than 12 months at the start of RSV season All those aged 12–24 months at the start of RSV season requiring medications in past 6 months	Children aged younger than 24 months at the start of RSV season requiring additional medical support
HS-CHD	Children 24 months of age or younger at the start of RSV season	All children aged younger than 12 months at the start of RSV season	All children aged younger than 24 months at RSV season start, unless cardiology waiver is obtained

Note. AAP = American Academy of Pediatrics; BPD = bronchopulmonary dysplasia; CLDP = chronic lung disease of prematurity; HS-CHD = hemodynamically significant congenital heart disease; NPA = National Perinatal Association; RSV = respiratory syncytial virus; wGA = weeks’ gestational age.